Bank of America Corp DE Has $855,000 Stock Holdings in OPKO Health, Inc. (NASDAQ:OPK)

Bank of America Corp DE lifted its stake in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 94.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 581,582 shares of the biotechnology company's stock after purchasing an additional 282,844 shares during the period. Bank of America Corp DE owned 0.09% of OPKO Health worth $855,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Capital Advisors Inc. OK acquired a new stake in OPKO Health in the 4th quarter valued at about $220,000. Ieq Capital LLC acquired a new stake in shares of OPKO Health in the fourth quarter valued at approximately $52,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of OPKO Health in the fourth quarter valued at approximately $102,000. Raymond James Financial Inc. bought a new position in shares of OPKO Health during the 4th quarter worth approximately $221,000. Finally, Essential Planning LLC. acquired a new position in shares of OPKO Health during the 4th quarter worth approximately $506,000. 64.63% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have issued reports on OPK shares. JPMorgan Chase & Co. assumed coverage on OPKO Health in a report on Friday, April 25th. They set a "neutral" rating for the company. HC Wainwright restated a "buy" rating and set a $3.00 target price on shares of OPKO Health in a research note on Monday, April 7th. Barrington Research reaffirmed an "outperform" rating and set a $2.25 target price on shares of OPKO Health in a report on Thursday, May 1st. Finally, Wall Street Zen cut shares of OPKO Health from a "hold" rating to a "sell" rating in a report on Monday, May 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, OPKO Health currently has an average rating of "Hold" and a consensus price target of $2.75.

OPKO Health Stock Performance

OPK stock traded down $0.01 during trading hours on Thursday, hitting $1.34. 2,487,516 shares of the stock were exchanged, compared to its average volume of 3,821,629. OPKO Health, Inc. has a 12 month low of $1.19 and a 12 month high of $2.04. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The firm has a market capitalization of $1.06 billion, a P/E ratio of -7.05 and a beta of 1.39. The company has a 50-day simple moving average of $1.37 and a two-hundred day simple moving average of $1.53.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.03). OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The business had revenue of $149.90 million for the quarter, compared to the consensus estimate of $163.13 million. During the same period in the prior year, the business posted ($0.12) earnings per share. OPKO Health's revenue was down 13.7% compared to the same quarter last year. On average, analysts forecast that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Phillip Md Et Al Frost bought 125,000 shares of OPKO Health stock in a transaction dated Thursday, April 10th. The shares were bought at an average cost of $1.36 per share, with a total value of $170,000.00. Following the acquisition, the chief executive officer now owns 214,001,448 shares in the company, valued at $291,041,969.28. This trade represents a 0.06% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders have acquired a total of 700,000 shares of company stock worth $1,123,000 in the last quarter. Corporate insiders own 49.69% of the company's stock.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.